This is amplified by the fact that the fusion proteins originating from the majority of the detected driver mutations, namely those of RET, NTRK3, CCDC6 (when co-occurs with RET), and MET, can be effectively targeted with small tyrosine kinase inhibitors in thyroid cancer [25,26,27]. The gene discussed is MET; the disease is thyroid gland carcinoma.